A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...